Pear Therapeutics, a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), and its wholly owned subsidiary, Pear Therapeutics (US), each voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware and they intend to pursue a sale of the business or assets under section 363 of the bankruptcy code.
Prior to the filing of the Chapter 11 cases, the debtors evaluated a wide range of strategic alternatives to maximize value for all stakeholders. The debtors also significantly reduced operating expenses. With the protections afforded by the bankruptcy code, the debtors intend to continue their marketing efforts to potential purchasers interested in specific assets as well as continuing to seek a sale of the whole business. Any of those sales would be subject to review and approval by the bankruptcy court and compliance with bidding procedures to be approved by the bankruptcy court.
The company intends to continue scaled-down operations during the Chapter 11 as it seeks to execute an expedited sale process. Having reached a settlement prior to the filing with its lender, Pear intends to use available cash to fund post-petition operations and costs in the ordinary course of its business.
The debtors intend to file various “first day” motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations. Such motions are typical in the Chapter 11 process and the debtors anticipate that they will be heard in the first few days of their Chapter 11 cases.
Pear is represented by Foley Hoag as counsel, Gibbons as co-counsel, Sonoran Capital Advisors as restructuring advisor, and MTS Health Partners as restructuring investment banker.
